Synthaverse Gets Marketing Authorization For Onko BCG In Serbia

About this update from Synthaverse Spolka Akcyjna

Synthaverse SA GPW:SVE:SAID ON THURSDAY IT HAS RECEIVED MARKETING AUTHORIZATION FOR ONKO BCG MEDICINAL PRODUCT IN SERBIAAPPLICATION FOR OBTAINING MARKETING AUTHORIZATION WAS SUBMITTED BY CORAPHARM, UNDER THE LICENSE GRANTED BY SYNTHAVERSEPLANS TO CONTINUE GLOBAL REGULATORY AND COMMERCIAL EXPANSION FOR BCG PRODUCTSSource text for Workspace:Further company coverage:

View stock analysis, news, and events for Synthaverse Spolka Akcyjna